Galectin Therapeutics (GALT) Misses Q3 EPS by 14c

Galectin Therapeutics (NASDAQ: GALT) reported Q3 EPS of ($0.24), $0.14 worse than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Adobe Systems (ADBE) Tops Q2 EPS by 14c, Offers Guidance
• Medtronic completes $550 million Scientia Vascular acquisition